Proposed Data Collections Submitted for Public Comment and Recommendations, 10219-10220 [E7-3986]
Download as PDF
<![CDATA[
10219
Federal Register / Vol. 72, No. 44 / Wednesday, March 7, 2007 / Notices
Form name &
number (CFR
reference)
Number of
respondents
Respondents
83.9 ...................
83.9 ...................
83.9 ...................
83.18 .................
Total ..........
Petitioners
Petitioners
Petitioners
Petitioners
Number of
responses per
respondent
Average
burden per respondent
(in hours)
using Form A ................................................
using Form B ................................................
not using Form B ..........................................
Appealing proposed decisions .....................
30
40
5
5
1
1
1
1
3/60
5
5.5
45/60
.........................................................................................
80
........................
........................
Dated: February 28, 2007.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–3985 Filed 3–6–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60-Day 07–07AN]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Joan Karr, CDC
Acting Reports Clearance Officer, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
Total burden
(in hours)
1.5
200
27.5
3.75
233
at a national corporation. The purpose
of the proposed evaluation is to
document in detail the workplace IPV
prevention activities delivered by the
company, to determine the impact of
these activities on short-term and longterm outcomes, and to determine the
cost-effectiveness of the program. All
managers at the corporation will be
screened to assess training experiences.
Then, more in-depth surveys will be
done among managers who have not
had the corporation’s IPV training. We
will survey those 500 managers at
baseline, and 6 and 12 months later.
Manager surveys will focus on
knowledge/awareness of IPV and
company resources for IPV and number
of referrals for IPV assistance. We will
also survey employees of those
managers using an anonymous webbased survey at baseline and 12 months
later to assess their self-evaluated
productivity, absenteeism, and
perceptions of manager behavior. We
will compare the responses of managers
(and their employees) who received the
IPV training in the study period (i.e.,
sometime between the baseline and 12
month surveys) with untrained
managers. The study will provide CDC
and employers information about the
potential effectiveness and costeffectiveness of workplace IPV
intervention strategies.
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Program Effectiveness Evaluation of
Workplace Intervention for Intimate
Partner Violence (IPV)—New—National
Center for Injury Prevention and
Control, Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Intimate partner violence (IPV) affects
a substantial number of Americans, and
there has recently been increasing
recognition of the impact it has on the
workplace. In addition to direct impacts
(batterers often stalk or even attack IPV
victims at their place of work), IPV has
indirect impacts on the workplace
environment through lost productivity
due to medical leave, absenteeism, and
fear and distraction on the part of
victims and coworkers. The Centers for
Disease Control and Prevention (CDC)
has employed contractor support to
evaluate an ongoing workplace IPV
prevention program being implemented
There are no costs to respondents
except their time to participate in the
interview.
ESTIMATE OF ANNUALIZED BURDEN HOURS
Average burden per response
(in hours)
Number of respondents
Number of responses per
respondent
Employee .........................................................................................................
Manager ...........................................................................................................
1500
500
2
3
30/60
30/60
1500
75
Total ..........................................................................................................
2000
........................
........................
2250
sroberts on PROD1PC70 with NOTICES
Respondents
VerDate Aug<31>2005
19:10 Mar 06, 2007
Jkt 211001
PO 00000
Frm 00108
Fmt 4703
Sfmt 4703
E:\FR\FM\07MRN1.SGM
07MRN1
Total burden
(in hours)
10220
Federal Register / Vol. 72, No. 44 / Wednesday, March 7, 2007 / Notices
Dated: February 28, 2007.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–3986 Filed 3–6–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Statement of Organization, Functions
and Delegation of Authority;
Republication
Editorial Note: FR Doc. E7–3306 originally
published at page 8742 in the issue of
Tuesday, February 27, 2007. The original
publication contained erroneous text. As a
result, the corrected document is being
republished in its entirety.
Notice is hereby given that I have
delegated to the Director, Office of Head
Start, the following authority vested in
me by the Secretary of Health and
Human Services in a memorandum
dated August 20, 1991, pertaining to the
Head Start Program and the Child
Development Associate Scholarship
Assistance Grants Program.
(a) Authority Delegated
Authority to administer the Head
Start Program under the Head Start Act,
42 U.S.C. 9801 et seq., and as amended
now and hereafter. (This includes
authority to administer the Early Head
Start program.)
sroberts on PROD1PC70 with NOTICES
(b) Limitations
1. This delegation of authority shall
be exercised under the Department’s
existing policies on delegations and
regulations.
2. This delegation of authority does
not include the authority to submit
reports to Congress and shall be
exercised under financial and
administrative requirements applicable
to all Administration for Children and
Families’ authorities.
3. The approval or disapproval of
grant applications including refunding
applications, the making of grant
awards, the waiver of non-Federal share
under 42 U.S.C. 9835(b), the waiver of
fifteen percent administrative cost
limitations under 42 U.S.C. 9839(b), and
the approval of interim grantees under
42 U.S.C. 9836(e) requires concurrence
of the appropriate Grants Officer. The
approval or disapproval of contract
proposals and awards is subject to the
requirements of the Federal Acquisition
Regulations and requires the
concurrence of the Contracting Officer.
VerDate Aug<31>2005
18:25 Mar 06, 2007
Jkt 211001
4. This delegation of authority does
not include the authority to approve or
disapprove awards for grants or
contracts for research, demonstration, or
evaluation under section 649 of the
Head Start Act.
5. This delegation of authority does
not include the authority to appoint
Central Office or Regional Office Grant
Officers for the administration of the
Head Start Program.
6. This delegation of authority does
not include the authority to appoint
Action Officials for Audit Resolution.
7. This delegation of authority does
not include the authority to sign and
issue notices of grant awards.
8. This delegation of authority does
not include the authority to hold
hearings. This limitation does not
include the ‘‘informal meetings’’
authorized in 45 CFR part 1303.
9. Any redelegation shall be in writing
and prompt notification must be
provided to all affected managers,
supervisors, and other personnel, and
requires the concurrence of the Deputy
Assistant Secretary for Administration.
(c) Effect on Existing Delegations
As related to this delegation of
authority, this delegation supersedes all
previous delegations of authority
involving the Head Start Program except
the September 25, 2002, delegation to
the Director, Office of Planning,
Research and Evaluation relating to
section 649 of the Head Start Act.
(d) Effective Date
This delegation is effective upon the
date of signature.
I hereby affirm and ratify any actions
taken by the Director, Office of Head
Start, which involved the exercise of the
authority delegated herein prior to the
effective date of this delegation.
Dated: February 16, 2007.
Wade F. Horn,
Assistant Secretary for Children and Families.
[FR Doc. E7–3306 Filed 2–26–07; 8:45 am]
Editorial Note: FR Doc. E7–3306 originally
published at page 8742 in the issue of
Tuesday, February 27, 2007. The original
publication contained erroneous text. As a
result, the corrected document is being
republished in its entirety.
[FR Doc. R7–3306 Filed 3–6–07; 8:45 am]
BILLING CODE 1505–01–D
PO 00000
Frm 00109
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N–0036]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Experimental
Study of Possible Footnotes and
Cueing Schemes to Help Consumers
Interpret Quantitative Trans Fat
Disclosure on the Nutrition Facts Panel
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
Fax written comments on the
collection of information by April 6,
2007.
DATES:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
4659.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance. In the Federal
Register of December 18, 2006 (71 FR
75762), FDA published a notice entitled
‘‘Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Experimental Study
of Possible Footnotes and Cueing
Schemes to Help Consumers Interpret
Quantitative Trans Fat Disclosure on the
Nutrition Facts Panel.’’ This notice
contained an incorrect deadline for
comments on the proposed collection of
information in the DATES section. FDA
is republishing the notice and providing
a full 30-day comment period. Any
comments previously submitted
regarding this notice will be considered
and do not need to be re-submitted.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\07MRN1.SGM
07MRN1
]]>Agencies
[Federal Register Volume 72, Number 44 (Wednesday, March 7, 2007)]
[Notices]
[Pages 10219-10220]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-3986]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60-Day 07-07AN]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-5960
and send comments to Joan Karr, CDC Acting Reports Clearance Officer,
1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
Program Effectiveness Evaluation of Workplace Intervention for
Intimate Partner Violence (IPV)--New--National Center for Injury
Prevention and Control, Centers for Disease Control and Prevention
(CDC).
Background and Brief Description
Intimate partner violence (IPV) affects a substantial number of
Americans, and there has recently been increasing recognition of the
impact it has on the workplace. In addition to direct impacts
(batterers often stalk or even attack IPV victims at their place of
work), IPV has indirect impacts on the workplace environment through
lost productivity due to medical leave, absenteeism, and fear and
distraction on the part of victims and coworkers. The Centers for
Disease Control and Prevention (CDC) has employed contractor support to
evaluate an ongoing workplace IPV prevention program being implemented
at a national corporation. The purpose of the proposed evaluation is to
document in detail the workplace IPV prevention activities delivered by
the company, to determine the impact of these activities on short-term
and long-term outcomes, and to determine the cost-effectiveness of the
program. All managers at the corporation will be screened to assess
training experiences. Then, more in-depth surveys will be done among
managers who have not had the corporation's IPV training. We will
survey those 500 managers at baseline, and 6 and 12 months later.
Manager surveys will focus on knowledge/awareness of IPV and company
resources for IPV and number of referrals for IPV assistance. We will
also survey employees of those managers using an anonymous web-based
survey at baseline and 12 months later to assess their self-evaluated
productivity, absenteeism, and perceptions of manager behavior. We will
compare the responses of managers (and their employees) who received
the IPV training in the study period (i.e., sometime between the
baseline and 12 month surveys) with untrained managers. The study will
provide CDC and employers information about the potential effectiveness
and cost-effectiveness of workplace IPV intervention strategies.
There are no costs to respondents except their time to participate
in the interview.
Estimate of Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Respondents Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Employee........................................ 1500 2 30/60 1500
Manager......................................... 500 3 30/60 75
---------------------------------------------------------------
Total....................................... 2000 .............. .............. 2250
----------------------------------------------------------------------------------------------------------------
[[Page 10220]]
Dated: February 28, 2007.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E7-3986 Filed 3-6-07; 8:45 am]
BILLING CODE 4163-18-P
